Cisplatin, Fluorouracil, and Tislelizumab

About

Membership operator: AND

Therapies: 3

Therapies

Cisplatin (tx:ncit:C376)

Fluorouracil (tx:ncit:C505)

Tislelizumab (tx:ncit:C121775)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy group.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab